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Objectives. Peptides delivered on the surface of influenza virosomes have been shown to induce solid humoral immune
responses in experimental animals. High titers of peptide-specific antibodies were also induced in a phase 1a clinical trial in
volunteers immunized with virosomal formulations of two peptides derived from the circumsporozoite protein (CSP) and the
apical membrane antigen 1 (AMA-1) of Plasmodium falciparum. The main objective of this study was to perform a detailed
immunological and functional analysis of the CSP-specific antibodies elicited in this phase 1a trial. Methodology/Principal
Findings. 46 healthy malaria-naı ¨ve adults were immunized with virosomal formulations of two peptide-phosphatidyletha-
nolamine conjugates, one derived from the NANP repeat region of P. falciparum CSP (designated UK-39) the other from P.
falciparum AMA-1 (designated AMA49-C1). The two antigens were delivered in two different concentrations, alone and in
combination. One group was immunized with empty virosomes as control. In this report we show a detailed analysis of the
antibody response against UK-39. Three vaccinations with a 10 mg dose of UK-39 induced high titers of sporozoite-binding
antibodies in all volunteers. This IgG response was affinity maturated and long-lived. Co-administration of UK-39 and AMA49-
C1 loaded virosomes did not interfere with the immunogenicity of UK-39. Purified total IgG from UK-39 immunized volunteers
inhibited sporozoite migration and invasion of hepatocytes in vitro. Sporozoite inhibition closely correlated with titers
measured in immunogenicity assays. Conclusions. Virosomal delivery of a short, conformationally constrained peptide
derived from P. falciparum CSP induced a long-lived parasite-inhibitory antibody response in humans. Combination with a
second virosomally-formulated peptide derived from P. falciparum AMA-1 did not interfere with the immunogenicity of either
peptide, demonstrating the potential of influenza virosomes as a versatile, human-compatible antigen delivery platform for
the development of multivalent subunit vaccines. Trial Registration. ClinicalTrials.gov NCT00400101
Citation: Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, et al (2007) A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-
Inhibitory Antibody Response in a Phase 1a Clinical Trial. PLoS ONE 2(12): e1278. doi:10.1371/journal.pone.0001278
INTRODUCTION
With over 300 million clinical episodes per year, malaria remains
one of the most important infectious diseases in humans [1]. More
than 30 years after the first successful protective vaccination of
man with attenuated sporozoites, vaccine development against
both Plasmodium falciparum and P. vivax is still ongoing [2,3]. The
most advanced experimental vaccine, RTS,S/AS02A, which is
based on the P. falciparum circumsporozoite protein (CSP), gave
35% protection against the first episode of malaria and 49%
protection against severe malaria for at least 18 month in a clinical
trial in Mozambican children [4,5]. Despite this success it is
assumed that a malaria vaccine that is more effective and more
cost effective than current malaria control tools, such as insecticide
treated bed nets and drug treatment will not be available in the
next ten years [6,7,8]. It is thought by many that a successful
malaria subunit vaccine will have to incorporate antigens against
several developmental stages of the parasite. A combination of
activities against sporozoites, infected liver cells, merozoites and
infected red blood cells may be required to achieve substantial
immune protection [9]. Vaccine development against malaria is
focusing largely on subunit technologies [9], where the major
obstacles include difficulties to retain the native conformation of
key antibody epitopes and the need for an effective but safe
human-compatible exogenous adjuvant [10]. A main advantage of
the subunit approach is that the ideal vaccine will induce immune
responses against only those determinants relevant to protection,
thus minimizing the possibility of deleterious responses.
We are addressing the problem of protein subunit vaccine
design by developing synthetic peptide structures and coupling
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virosomes (IRIVs) as a liposomal carrier system via a phosphatidyl-
ethanolamine (PE) anchor [11,12,13,14,15,16]. IRIVs are spherical,
unilamellar vesicles, prepared by detergent removal from a mixture
of natural and synthetic phospholipids and influenza surface
glycoproteins. Hemagglutinin, a membrane glycoprotein of the
influenza virus mediates binding to sialic acid on target cells and is a
fusion-inducing component, facilitating antigen delivery to immu-
nocompetent cells. IRIVs represent a universal antigen-delivery
system for multivalent subunit vaccines, since antigens can be either
attached to their surface to elicit antibody and CD4 T cell responses
orencapsulated intheirlumentoelicitCD8 T cellresponses[13,17].
They have an excellent safety profile and two virosomal vaccines
(against influenza and hepatitis A virus) are already registered for
human use in more than 40 countries [18].
We are optimizing synthetic peptides in an iterative selection
process to develop vaccine components with native-like confor-
mation that elicit high titers of parasite cross-reactive antibodies
[11,12,13,14,15,16,19,20]. Peptides are synthesized from antigens
that (i) have a documented and essential role in parasite
development, (ii) have secondary structure motifs suggesting
surface exposition, (iii) have conserved sequence stretches, and
(iv) induce parasite-inhibitory antibodies. Based on these criteria
we try to choose protein domains containing protection-relevant
epitopes, thus avoiding the induction of deleterious immune
responses as observed during infection with P. falciparum. Lead
peptides are optimized in a step-wise process. The key readout are
the parasite-binding properties of antibodies elicited in mice after
immunization with the corresponding peptide coupled to the
surface of IRIVs. After preclinical profiling in experimental
animals two candidate peptides, i.e. AMA49-C1, a 49-aa cyclic
peptide derived from loop I of domain III of P. falciparum apical
membrane antigen 1 (AMA-1) [13], and UK-39, a conformation-
ally constrained cyclic peptide containing five NPNA repeats
derived from the central repeat region of P. falciparum CSP [15],
have been tested in a phase 1a clinical trial. Virosomal
formulations of AMA49-C1 (designated PEV301) and UK-39
(designated PEV302) were both safe and elicited anti-peptide IgG
in all volunteers immunized with an appropriate peptide
concentration [21]. In this report we focus on the detailed
immunogenicity data for this first clinical trial with PEV302.
Complete results for PEV301 will be presented elsewhere. While
mean ELISA titer development for the different vaccination
groups has been described previously [21], we analyze and
correlate here anti-peptide ELISA titers with titers of parasite
cross-reactive antibodies and with parasite-inhibitory activities at
the level of individual sera. Moreover, we show affinity maturation
of UK-39-specific antibodies induced by vaccination.
MATERIALS AND METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Serum samples were collected during a phase 1a clinical trial at the
Clinical Research Center, University Hospital, Basel, Switzerland.
Details of the study design are described in a separate report [21].
Briefly, a prospective phase 1a, single blind, randomized, placebo
controlled, dose-escalating study was conducted in 46 healthy
malaria-naı ¨ve adult volunteers.
Eligible study participants were randomized into six groups
receiving virosomal formulations of the following antigens: 10 mg
AMA49-C1 (group A, n=8), 10 mg UK-39 (group B, n=8), 50 mg
AMA49-C1 (group C, n=8), 50 mg UK-39 (group D, n=8), 50 mg
AMA49-C1+50 mg UK-39 (mixture of separate virosome-prepara-
tions containing one antigen each) (group E, n=8) or empty IRIVs
serving as controls (group F, n=6). In this report we only used
samples from PEV302 immunized individuals and controls.
Vaccine
Two virosomally-formulated vaccines, PEV301 (incorporating the
AMA-1 derived PE-peptide conjugate AMA49-C1 [13]) and
PEV302 (incorporating the CSP derived PE-peptide conjugate
UK-39 [15]) were produced according to the rules of GMP. Tests
for sterility, pyrogenicity, immunogenicity in animals, stability and
chemical composition were performed on the vaccine lots used in
this trial. Each dose was composed of 10 or 50 mg AMA49-C1 or
UK-39, 10 mg Influenza hemagglutinin, 100 mg phospholipids and
PBS ad 0.500ml. Volunteers immunized with a combination of
virosomally formulated AMA49-C1 and UK-39 received a double
dose of influenza proteins. The vaccine was stored at 4uC. The
immunization regimen was 0, 2 and 6 months. The trial vaccines
were administered i.m. in the left arm on day 0, in the right one on
day 56–65, and in the left again on day 175–186.
Immunogenicity
Blood sampling for antibody titer measurement by ELISA, IFA
and Western blot was done at screening visit (baseline and 1
st
vaccination), at the days of the 2
nd and 3
rd vaccination, 21 days
after each vaccination and one year after the third vaccination
(groups B and E only). Serum from volunteers with no history of
malaria was used as a negative control and serum from an
individual living in a malaria endemic area was used as a positive
control for IFA and Western blotting studies.
ELISA
Standard ELISAs were performed as described before [13].
Briefly, Polysorp
TM microtiter plates (Nunc, Dr. Grogg, Stetten-
Deiswill, Switzerland) were coated with 10 mg/ml AMA49-C1 or
UK-39 in PBS. After blocking, plates were incubated with two-fold
serial dilutions of human serum. Horseradish-peroxidase-conju-
gated goat anti-human IgG antibodies (KPL, Socochim, Lau-
sanne, Switzerland) were used as secondary antibodies and 1,2-
Diaminobezene substrate (OPD) (Fluka, Sigma, Buchs, Switzer-
land) in citrat-buffer (4mg/ml OPD)+0.01% H2O2 for develop-
ment. The endpoint titer is the last serum dilution where the
ODtest sera$26ODnegativ serum pool. The negative serum pool is
from 10 non-immunized malaria-naı ¨ve individuals living in
Switzerland.
NH4SCN elution ELISA
Avidity ELISA analyses with peptide-PE conjugates were
performed essentially as described before [22]. After coating and
blocking, as described for standard ELISA, serum samples were
added in triplicates at constant dilutions (approx. halfmax titer).
After a wash step, plates were incubated 15min with NH4SCN
diluted in 0.1M NaH2PO4 buffer (pH 6) at the following
molarities: 5M, 4M, 3M, 2M, 1M, 0.5M, 0.25M. Control wells
were incubated with 0.1M NaH2PO4 buffer without NH4SCN.
After washing, plates were incubated with alkaline phosphatase-
conjugated affinity-pure F(ab)2 fragment goat anti-human IgG (Fc-
specific) antibodies (Jackson Immuno Research Laboratories, West
Grove, PA) and developed with phosphatase substrate solution.
The avidity index corresponds to the NH4SCN concentration (M)
eluting 50% of the bound antibodies.
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IFAs were performed as described before [15]. Air-dried unfixed
P. falciparum (strain NF54) salivary gland sporozoites attached to
microscope glass slides were incubated with serial dilutions of sera
and detected with Cy
TM3-conjugated affinity-pure F(ab)2 fragment
goat anti-human IgG (Fc-specific) antibodies (Jackson Immuno
Research Laboratories, West Grove, PA) diluted in blocking
solution containing 0.01 mg/ml Hoechst dye no. 33256 (Sigma,
St. Louis, MO).
SDS-PAGE and immunoblotting
Anopheles stephensi salivary gland lysate containing about 100,000 P.
falciparum sporozoites was separated on a 10% SDS PAGE mini-gel
and transferred to a nitrocellulose filter as described before [13].
Filter strips were incubated with serial dilutions of sera. Monoclonal
antibody EP9 served as a positive control [14]. Antibodies were
detected with alkaline peroxidase-conjugated affinity-pure F(ab’)2
fragment goat anti-human IgG (Fc-specific) antibodies (Jackson
Immuno Research Laboratories, West Grove, PA) Blots were
developed using ECL
TM Western blotting detection reagents
(Amersham Biosciences, Buckinghamshire, England).
P. falciparum in vitro invasion inhibition assay
Blinded inhibition assays were performed as described before [23].
Briefly, triplicate primary human hepatocyte cultures were inocu-
lated withP.falciparumsporozoites(1610
5/Lab-Tekwell).After3hat
37uC, cultures were washed, further incubated in fresh medium for
3 days, and fixed in methanol. Quantification of exoerythrocytic
forms was done by immunofluorescence. To determine the effects of
anti-UK-39 antibodies on sporozoite infectivity, sporozoites were
incubated with hepatocytes in the presence of affinity purified
polyclonal human IgG from immunized volunteers. Inhibition was
determined in comparison to PBS control.
P. falciparum migration inhibition assay
Blinded migration inhibition assays were performed as described
before [24]. Briefly, HepG2 cells were incubated with sporozoites in
the presence of cell-impermeant tracer fluorescein isothiocyanate
(FITC)-dextran. After 2 hours at 37uC cells were washed to remove
extracellular FITC-dextran and analyzed by flow cytometry.
Inhibition was determined in comparison to PBS control.
Statistical analysis
Statistical significance of increases in avidity was tested using a
Wilcoxon signed-rank test to compare avidity indices between
different time points. Correlation of titers in immunogenicity
assays and correlations of titers with inhibition was analyzed with
nonparametric (Spearman) correlation. Pearson correlation coef-
ficients were used to assess correlation of invasion and migration
inhibition. Average titers are displayed as geometric means. The
level of significance used was 0.05 for all analyses. No adjustments
were made for multiple comparisons. All statistical analyses and
graphs were made using GraphPad Prism version 4.03 for
Windows, GraphPad Software, San Diego, CA.
RESULTS
Details on study design, safety and basic immunogenicity data of
this trial are reported in a separate study [21].
Outcomes and estimation
Development of IgG responses against the synthetic antigen
UK-39 Already after two immunizations, all volunteers receiving
the virosomal formulation of 10 mg UK-39 alone (group B) or
50 mg UK-39 in combination with 50 mg of AMA49-C1 (group E)
had developed an anti-UK-39 IgG response with an endpoint titer
above 400 in ELISA (Figure 1), as shown before [21]. In group D
receiving 50 mg of UK-39 alone, five out of seven volunteers (71%;
exact binomial 95% CI=29%, 96%) had sero-converted after two
immunizations with titers above 600. A further increase in IgG titer
afterthethirdimmunizationwasobservedonlyinsomevolunteersin
allvaccinationgroups.Aone-yearfollow-upwasperformedwithone
group for each of the two antigens and for the combination. One
year after the third immunization titers had dropped, but all
volunteers of groupsB andE remained positive(endpoint titer .10
2)
in ELISA. No increase in anti-UK-39 antibody titers after
vaccination was observed in volunteers of the control group F
receiving empty IRIVs (Figure 1). The overall highest endpoint titer
(.10
6) was observed after the first immunization in a volunteer (35/
D) from the 50 mg UK-39 group, which had a pre-immunization
ELISA endpoint titer of about 10
3 (Figure 1).
Antibody affinity maturation is a key event during memory B
cell development. We measured the avidity of anti-UK-39 IgG in
elution ELISAs with chaotropic salt. The mean avidity of the
vaccine-induced IgG responses gradually increased by two-fold in
all groups over the course of immunization (Figure 2). Volunteer
35/D who had pre-existing UK-39 cross-reactive antibodies had
high-affinity anti-UK-39 IgG already after the first immunization.
Ancillary analyses
Sporozoite cross-reactivity of anti-UK-39 IgG responses
After three immunizations all volunteers (14/14) immunized with
10 mg UK-39 or 50 mg UK-39 combined with 50 mg AMA49-C1
and five of seven volunteers (71%; exact binomial 95% CI=29%,
96%) immunized with 50 mg UK-39 alone showed a vaccine-
induced increase in IgG that was cross-reactive (endpoint titers
$10
2)w i t hP. falciparum sporozoites in IFA and in Western blotting
(Figure 3). Mean IFA and Western blotting endpoint titers increased
with each of the three immunizations. One year after the third
immunization ten out of eleven (91%; exact binomial 95%
CI=59%, 99.8%) volunteers in the 10 mg UK-39 and the
combination group were still positive (endpoint titers $10
2). IRIVs
alone (group F) did not elicit parasite cross-reactive IgG; volunteer
12/Fwhohad exhibitedapersistentanti-UK-39ELISAtiteralready
present before the first vaccination also had an IFA and Western
blotting titer.
Statistical analysis of ELISA, IFA and Western blotting titers
(from all volunteers and time-points measured) revealed a close
correlation between all assays. Spearman’s rank correlation
coefficients were r=0.892 (P,0.0001) for the comparison of titers
in ELISA and IFA, r=0.703 (P,0.0001) for the comparison of
titers in ELISA and Western blot, and r=0.649 (P=0.0001) for
the comparison of titers in IFA and Western blot.
Volunteer 35/D, who had a pre-immune ELISA titer that
strongly increased by just one immunization, also developed very
high IFA and Western blotting titers (10
5) after the first
immunization (Figure 4A). While this volunteer had a pre-existing
Western blotting (Figure 4B) and ELISA titer of 10
3, no IFA
staining was observed with the pre-immune serum (Figure 4C).
Sporozoite inhibitory activity
Anti-sporozoite antibodies can interfere with critical steps of
sporozoite development like migration through tissues [24,25] and
invasion of hepatocytes [26]. To test the impact of anti-UK-39
antibodies on sporozoite infectivity we used two different in vitro
assays measuring sporozoite migration through hepatocytes
Peptide Malaria Vaccine Trial
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presence of purified IgG from immunized volunteers.
Migration inhibition experiments were performed as described
by Mota et al. [24]. Sporozoites were incubated with HepG2 cells
in the presence of cell-impermeant FITC-dextran. Wounded cells
take up FITC-dextran, which is trapped in the cell cytoplasm after
wound resealing and can be detected by flow cytometry. Total IgG
from nine volunteers from all immunization groups representing
the whole range of observed immune responses (including controls)
were purified. The presence of purified total IgG (final
concentration 1mg/ml) from UK-39-immunized volunteers re-
duced sporozoite migration in a dose dependent manner.
Vaccination-induced increases in migration inhibitory activity
were observed in all seven UK-39-immunized volunteers
(Figure 5A). There was a trend to higher rates of inhibition in
group B compared to group E immunized with the combination
vaccine. This observation was statistically significant (two-sided
unpaired t test, P=0.0005) but not relevant due to the small
sample size. IgG preparations from control individuals, immu-
nized with AMA49-C1 or IRIVs alone showed no vaccine-
induced inhibition of sporozoite migration (data not shown).
The impact of antibodies on sporozoite invasion can be
determined in invasion inhibition assays where the development of
liver stage parasites after incubation of primary human hepatocyte
cultures with P. falciparum sporozoites is quantified. Vaccine-induced
inhibition of sporozoite invasion was seen with purified IgG (final
concentration 1mg/ml) from six out of the same seven volunteers
immunized with UK-39, and analyzed for migration inhibition
(Figure 5B). No effect of dose and formulation of the vaccine on the
inhibitory potential of the induced antibodies was observed. IgG
preparations from controls immunized with AMA49-C1 or IRIVs
did not inhibit sporozoite invasion (data not shown). Boosting of a
pre-existing UK-39 cross-reactive antibody response in volunteer
35/D (Figure 4) induced IgG with high migration and invasion
inhibitory potential showing no difference to IgG preparations of
other UK-39-immunized volunteers (Figure 5A and B).
We found a strong correlation (Pearson correlation r=0.8648,
P,0.0001) between inhibition of invasion and inhibition of
migration by IgG preparations (Figure 6). To determine a relation
between this functional activity and the immunogenicity results we
also compared IgG titers measured in ELISA, IFA and Western
blotting with inhibition results. IgG titers measured in all three
immunogenicity assays closely correlated with the migration and
invasion inhibitory activity of the antibodies (data not shown for
invasion inhibition) (Figure 6).
DISCUSSION
Interpretation
In this report we describe immunological and functional properties
of antibodies elicited by the virosomally formulated synthetic
peptide UK-39 in a phase 1a clinical trial. Since virosomally
Figure 1. ELISA endpoint titers. Shown are anti-UK-39 IgG ELISA endpoint titers for individual volunteers of all vaccination groups at baseline (0) and
21 days after each vaccination and one year after the third vaccination. Arrows indicate days of immunization. Only the groups immunized with
10 mg UK-39 or 50 mg UK-39+50 mg AMA49-C1 were followed up for one year.
doi:10.1371/journal.pone.0001278.g001
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surface of IRIVs, they have the potential to amplify the antigen-
specific B cell pool enormously, allowing a very early and efficient
switch to a long-lived IgG response [27,28]. Two immunizations
with 10 mg UK-39 were indeed enough to induce high titers of
peptide-specific IgG in all volunteers [21]. A higher dose of 50 mg
peptide delivered with the same amount of IRIVs was not superior
in terms of sero-conversion and mean antibody titers elicited.
However, when co-administered with a second virosomal vaccine
component, the 50 mg dose of UK-39 was as immunogenic as the
10 mg dose alone. This may be related to the doubling of the
amount of influenza antigens administered with the combination
vaccine and the adjuvant-effect associated with the viral
components. All volunteers had pre-existing influenza T cell and
antibody responses, but no correlation with the magnitude of the
responses against the malaria antigens were observed (Peduzzi et
al., personal communication).
One volunteer (35/D) of the 50 mg UK-39 group needs special
attention. Pre-immune serum of this volunteer already contained
antibodies that were reactive with UK-39 in ELISA and with CSP
in Western blotting. This cross-reactivity, which was not related to
a known history of malaria exposure, was exceptionally boosted
already by the first immunization, yielding the highest titers
observed in the entire trial. Even though the observed pre-existing
humoral response was not malaria-related, this suggests that IRIV-
based vaccines might have the potential to boost natural
immunity. It is therefore highly likely, that two or even one
vaccine dose may be sufficient to boost pre-existing immunity in
vaccine recipients from endemic areas.
We found a close correlation between IgG titers against the
peptide UK-39 in ELISA and IgG titers in IFA and Western
blotting with whole parasites and parasite-derived antigens,
respectively. Moreover titers in these immunogenicity assays were
closely correlating with in vitro inhibition of sporozoite migration
and invasion of hepatocytes. This confirms the observation that
the conformationally restrained peptide UK-39 is very close to the
natural conformation of the NANP repeats, as already indicated
by NMR analysis of UK-39 and the crystal structure of an NPNA
repeat [15,29].
Vaccine induced immunity has to include formation of
immunological memory, the key to successful immune protection
[30]. One crucial step of memory formation is antibody affinity
maturation in germinal centers where high-affinity variants of
antigen-specific B cells are selected for entry into the long-lived
memory B cell compartment [31]. We found an increase in anti-
UK-39 antibody avidity over the course of immunization in all
three vaccine groups indicating memory B cell formation. The
mean avidity index was highest in group D receiving 50 mg of UK-
Figure 2. Affinity maturation of vaccine-induced IgG. Median of avidity indices for the anti-UK-39 IgG responses in all vaccination groups receiving
UK-39 three weeks after the first, second and third immunization. The avidity index is the NH4SCN concentration (M) where 50% of the bound
antibodies are eluted. Shown are results obtained with individual sera and the median (line) for each time point. Wilcoxon signed-rank test was used
to calculate the statistical significance of a difference in avidity between the third and the first vaccination.
doi:10.1371/journal.pone.0001278.g002
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1278Figure 3. Cross-reactivity of vaccine-induced IgG with P. falciparum sporozoites. IFA (left panel) and Western blotting (right panel) were performed
with P. falciparum salivary gland sporozoites. Shown are endpoint titers and number of volunteers showing an increase in titer compared to pre-
immune (pI) serum. Note that the volunteers in the 50 mg group who gave positive results before the first immunization showed no increase in titer
upon vaccination. Blood samples were taken pre-immune, three weeks after the first, second and third immunization and one year after the third
immunization. Lines represent the geometric mean of all volunteers in the respective group. Arrows indicate volunteer 35/D that had a pre-existing
anti-UK39 IgG ELISA titer of 10
3. Only the groups immunized with 10 mg UK-39 or 50 mg UK-39+50 mg AMA49-C1 were followed up for one year.
doi:10.1371/journal.pone.0001278.g003
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and 36/D). One year after the third immunization all volunteers
receiving the 10 mg dose of UK-39 had remained positive in
ELISA, Western blotting analysis and IFA supporting the
hypothesis that vaccination with virosomally formulated UK-39
has induced long-term IgG production by long-lived plasma cells.
One of the major problems associated with malaria vaccine
development are missing in vitro and in vivo correlates of
protection. Various in vitro assays and experimental animal
models are available to test functional activity of induced
responses, but the predictive value of these systems cannot be
determined until the results are correlated with clinical efficacy of
vaccine candidates [32]. No in-depth study comparing in vitro
results, animal studies, artificial human challenge and vaccine
efficacy in endemic areas has been reported to date. Furthermore,
standardized assays to evaluate functional activity of vaccine-
induced antibodies with a validated set of control sera would be
most desirable for future malaria vaccine development.
Induction of antibodies inhibiting in vitro sporozoite migration,
growth, and development was observed in a majority of UK-39-
immunized volunteers tested, regardless of vaccine formulation.
Inhibition was IgG concentration-dependent and confirmed data
obtained with animal sera [15]. Inhibition of sporozoite migration
and invasion was observed at concentrations of total purified IgG
from immunized volunteers that were more than ten times lower
than the physiological IgG concentration of about 13 mg/ml.
Even though this inhibition might only be partial and would not
prevent the development of blood-stage infection, previous
experience with sporozoite vaccines and insecticide treated
bednets has shown that reduction of merozoites released from
the liver can decrease the occurrence of severe forms of disease
[5,33]. It will be crucial to follow-up these inhibition results in
phase 2a challenge trials and efficacy studies in field trials to
validate these in vitro inhibition assays as correlates for protection.
Invasion inhibition was positively correlated with migration
inhibition, suggesting that anti-UK-39 antibodies interfered with
parasite gliding motility, which is based on the same mechanism of
redistribution of proteins along the sporozoite surface as host cell
invasion [34]. Whether inhibition is due to a specific block of a
component of the machinery necessary for gliding or by steric
Figure 4. Boost of a pre-existing anti-UK-39 cross-reactive antibody response in volunteer 35/D. A: Comparison of ELISA, IFA and Western blotting
titers of pre-immune serum and sera taken three weeks after each immunization. Shown are representative titers from one out of three experiments.
B: Western blotting results obtained with serum taken before and three weeks after the first immunization. Dilutions are: 1, 1:200; 2, 1:400; 3, 1:800;4 ,
1:3,000; 5, 1:9,000; 6, 1:27,000; 7, 1:81,000; 8, 1:243,000; 9, 1:729,000; 10, 1:2,187,000; 11, 1:6,561,000; 12, Positive control anti-NANP mAb EP9. C: IFA on
P. falciparum sporozoites with serum taken before and three weeks after the first immunization. An overlay of DNA staining with Hoechst dye no.
33256 (blue) and Cy3-immunofluorescence staining (red) is shown.
doi:10.1371/journal.pone.0001278.g004
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PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e1278Figure 5. Functional activity of anti-UK39 IgG responses. Sporozoite migration and invasion inhibition by IgG preparations (final concentration
1 mg/ml) purified from sera taken before the first (pI) and three weeks after the third immunization (3.imm). Three volunteers (xy/B) immunized with
10 mg UK-39, one volunteer (35/D) immunized with 50 mg UK-39, and three volunteers (xy/E) immunized with 50 mg UK-39+50 mg AMA49-C1 were
chosen. Shown are the means and standard deviation from at least two independent experiments. A: In vitro inhibition of sporozoite migration
through human HepG2 cells. B: In vitro Inhibition of sporozoite invasion of primary human hepatocytes.
doi:10.1371/journal.pone.0001278.g005
Figure 6. Correlation (r) of functional activity with antibody titers. Sera taken before the first and three weeks after the third immunization from
eight PEV302 immunized volunteers plus one IRIV control and one control from group C immunized with PEV301 alone (only post immunization)
analyzed in inhibition assays were included in the analysis. Pearson correlation coefficients were calculated for correlation of invasion and migration
inhibition; nonparametric (Spearman) correlation was used for analysis of immunogenicity assays.
doi:10.1371/journal.pone.0001278.g006
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correlation of results in invasion inhibition experiments and the far
easier migration inhibition assays, the migration inhibition system
might be a valuable second line method to measure the biological
activity of anti-CSP antibodies. Further advantages of the migration
inhibition assays are the reduced time needed, the option for
quantitativeanalysisbyflowcytometryand thepossibility to perform
the experiments with hepatocyte cell lines. Altogether, these
properties make the migration inhibition assay an interesting tool
for screening large numbers of serum samples in clinical trials.
Overall evidence
These results demonstrate the suitability of IRIVs as a human-
compatible carrier/adjuvant system for the induction of potent
humoral immune responses against synthetic peptide antigens.
The CSP-specific humoral immune responses characterized in this
report were very uniform, cross-reactive with P. falciparum, affinity
maturated, long-lived and parasite-inhibitory. Combination of two
components had no negative effect on the elicited immune
response against the single components, showing the potential of
influenza virosomes as a versatile antigen delivery platform for
multivalent vaccine development.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001278.s001 (0.05 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001278.s002 (0.32 MB
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